Search Results - "Kantoff, PW"

Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in vivo by Farokhzad, Omid C., Cheng, Jianjun, Teply, Benjamin A., Sherifi, Ines, Jon, Sangyong, Kantoff, Philip W., Richie, Jerome P., Langer, Robert

“…Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate…”
Get full text

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A by Sun, T, Wang, X, He, H H, Sweeney, C J, Liu, S X, Brown, M, Balk, S, Lee, G-SM, Kantoff, P W

“…Hormone-sensitive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the androgen deprivation therapy. We investigated…”
Get full text

Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men by Krithivas, K, Yurgalevitch, SM, Mohr, BA, Wilcox, CJ, Batter, SJ, Brown, M, Longcope, C, McKinlay, JB, Kantoff, PW

“…In men over 30 years old, serum levels of testosterone (T) decrease with age. A shorter polymorphic CAG repeat length in exon 1 of the androgen receptor (AR)…”
Get full text

6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial by D'Amico, Anthony V, Manola, Judith, Loffredo, Marian, Renshaw, Andrew A, DellaCroce, Alyssa, Kantoff, Philip W

“…CONTEXT Survival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years…”
Get full text

SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis by Rajanala, Sai Harisha, Plym, Anna, Vaselkiv, Jane B, Ebot, Ericka M, Matsoukas, Konstantina, Lin, Zhike, Chakraborty, Goutam, Markt, Sarah C, Penney, Kathryn L, Lee, Gwo-Shu M, Mucci, Lorelei A, Kantoff, Philip W, Stopsack, Konrad H

“…Abstract Solute carrier organic anion (SLCO) transporters (OATP transporters) are involved in cellular uptake of drugs and hormones. Germline variants in…”
Get full text

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort by DEMICHELIS, F, FALL, K, ADAMI, H.-O, MUCCI, L. A, KANTOFF, P. W, ANDERSSON, S.-O, CHINNAIYAN, A. M, JOHANSSON, J.-E, RUBIN, M. A, PERNER, S, ANDREN, O, SCHMIDT, F, SETLUR, S. R, HOSHIDA, Y, MOSQUERA, J.-M, PAWITAN, Y, LEE, C

“…The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical…”
Get full text

Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression by Hendrickson, Whitney K, Flavin, Richard, Kasperzyk, Julie L, Fiorentino, Michelangelo, Fang, Fang, Lis, Rosina, Fiore, Christopher, Penney, Kathryn L, Ma, Jing, Kantoff, Philip W, Stampfer, Meir J, Loda, Massimo, Mucci, Lorelei A, Giovannucci, Edward

“…Data suggest that circulating 25-hydroxyvitamin D [25(OH)D] interacts with the vitamin D receptor (VDR) to decrease proliferation and increase apoptosis for…”
Get full text

Autoantibody Signatures in Prostate Cancer by Wang, Xiaoju, Yu, Jianjun, Sreekumar, Arun, Varambally, Sooryanarayana, Shen, Ronglai, Giacherio, Donald, Mehra, Rohit, Montie, James E, Pienta, Kenneth J, Sanda, Martin G, Kantoff, Philip W, Rubin, Mark A, Wei, John T, Ghosh, Debashis, Chinnaiyan, Arul M

“…This article describes a new method of detecting autoantibodies against prostate cancer antigens in the serum of patients with prostate cancer. The method…”
Get full text

Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG by PETTERSSON, Andreas, LIS, Rosina T, NUTTALL, Elizabeth J, MARTIN, Neil E, SESSO, Howard D, POLLAK, Michael, STAMPFER, Meir J, KANTOFF, Philip W, GIOVANNUCCI, Edward L, LODA, Massimo, MUCCI, Lorelei A, MEISNER, Allison, FLAVIN, Richard, STACK, Edward C, FIORENTINO, Michelangelo, FINN, Stephen, GRAFF, Rebecca E, PENNEY, Kathryn L, RIDER, Jennifer R

“…TMPRSS2:ERG is a hormonally regulated gene fusion present in about half of prostate tumors. We investigated whether obesity, which deregulates several hormonal…”
Get full text

Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer by Setlur, Sunita R., Mertz, Kirsten D., Hoshida, Yujin, Demichelis, Francesca, Lupien, Mathieu, Perner, Sven, Sboner, Andrea, Pawitan, Yudi, Andrén, Ove, Johnson, Laura A., Tang, Jeff, Adami, Hans-Olov, Calza, Stefano, Chinnaiyan, Arul M., Rhodes, Daniel, Tomlins, Scott, Fall, Katja, Mucci, Lorelei A., Kantoff, Philip W., Stampfer, Meir J., Andersson, Swen-Olof, Varenhorst, Eberhard, Johansson, Jan-Erik, Brown, Myles, Golub, Todd R., Rubin, Mark A.

“…Background The majority of prostate cancers harbor gene fusions of the 5′-untranslated region of the androgen-regulated transmembrane protease serine 2…”
Get full text

Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? by Zhou, Charlie D, Pettersson, Andreas, Plym, Anna, Tyekucheva, Svitlana, Penney, Kathryn L, Sesso, Howard D, Kantoff, Philip W, Mucci, Lorelei A, Stopsack, Konrad H

“…Older age at diagnosis is consistently associated with worse clinical outcomes in prostate cancer. We sought to characterize gene expression profiles of…”
Get full text

Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer by Stopsack, Konrad H, Gerke, Travis, Zareba, Piotr, Pettersson, Andreas, Chowdhury, Dipanjan, Ebot, Ericka M, Flavin, Richard, Finn, Stephen, Kantoff, Philip W, Stampfer, Meir J, Loda, Massimo, Fiorentino, Michelangelo, Mucci, Lorelei A

“…Abstract DNA repair genes are commonly altered in metastatic prostate cancer, but BRCA1 mutations are rare. Preliminary studies suggest that higher tumor…”
Get full text

Gene expression correlates of clinical prostate cancer behavior by Singh, Dinesh, Febbo, Phillip G., Ross, Kenneth, Jackson, Donald G., Manola, Judith, Ladd, Christine, Tamayo, Pablo, Renshaw, Andrew A., D'Amico, Anthony V., Richie, Jerome P., Lander, Eric S., Loda, Massimo, Kantoff, Philip W., Golub, Todd R., Sellers, William R.

“…Prostate tumors are among the most heterogeneous of cancers, both histologically and clinically. Microarray expression analysis was used to determine whether…”
Get full text

Tumor protein expression of BRCA1 and development of lethal prostate cancer by Ceraolo, Carl, Gerke, Travis A., Zareba, Piotr, Pettersson, Andreas, Stopsack, Konrad H., Chowdhury, Dipanjan, Ebot, Ericka M., Flavin, Richard, Finn, Stephen P., Kantoff, Philip W., Stampfer, Meir J., Loda, Massimo, Fiorentino, Michelangelo, Mucci, Lorelei A.

“…Abstract only 65 Background: DNA repair genes including BRCA1 are commonly altered in metastatic prostate tumors. However, mutations and copy number…”
Get full text

Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer by HALABI, Susan, SMALL, Eric J, KANTOFF, Philip W, KATTAN, Michael W, KAPLAN, Ellen B, DAWSON, Nancy A, LEVINE, Ellis G, BLUMENSTEIN, Brent A, VOGELZANG, Nicholas J

“…To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients…”
Get full text

Changes in body composition during androgen deprivation therapy for prostate cancer by SMITH, Matthew R, FINKELSTEIN, Joel S, MCGOVERN, Francis J, ZIETMAN, Anthony L, FALLON, Mary Anne, SCHOENFELD, David A, KANTOFF, Philip W

“…The aim of this study was to determine the effects of initial treatment with a GnRH agonist on body composition in asymptomatic men with nonmetastatic prostate…”
Get full text

Family history of prostate cancer and the incidence of ERG‐ and phosphatase and tensin homolog‐defined prostate cancer by Hashim, Dana, Gonzalez‐Feliciano, Amparo G., Ahearn, Thomas U., Pettersson, Andreas, Barber, Lauren, Pernar, Claire H., Ebot, Ericka M., Isikbay, Masis, Finn, Stephen P., Giovannucci, Edward L., Lis, Rosina T., Loda, Massimo, Parmigiani, Giovanni, Lotan, Tamara, Kantoff, Philip W., Mucci, Lorelei A., Graff, Rebecca E.

“…Family history is among the strongest known risk factors for prostate cancer (PCa). Emerging data suggest molecular subtypes of PCa, including two somatic…”
Get full text

Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer by Smith, Matthew R, McGovern, Francis J, Zietman, Anthony L, Fallon, Mary Anne, Hayden, Douglas L, Schoenfeld, David A, Kantoff, Philip W, Finkelstein, Joel S

“…A second-generation bisphosphonate appears to prevent this bone loss due to androgen-deprivation therapy. Prostate cancer is the most common cancer and the…”
Get full text

The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies by Pettersson, Andreas, Gerke, Travis, Fall, Katja, Pawitan, Yudi, Holmberg, Lars, Giovannucci, Edward L., Kantoff, Philip W., Adami, Hans‐Olov, Rider, Jennifer R., Mucci, Lorelei A.

“…There has been limited success in identifying prognostic biomarkers in prostate cancer. A partial explanation may be that insufficient emphasis has been put on…”
Get full text

Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era by PLATZ, Elizabeth A, LEITZMANN, Michael F, RIFAI, Nader, KANTOFF, Philip W, CHEN, Yen-Ching, STAMPFER, Meir J, WILLETT, Walter C, GIOVANNUCCI, Edward

“…Objective: Sex steroid hormones are thought to contribute to the growth, differentiation, and progression of prostate cancer. We investigated plasma levels of…”
Get full text